ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 0076

The Role of Interferon Kappa in Psoriasis

Mehrnaz Gharaee-Kermani1, Shannon Estadt2, Sonya Wolf-Fortune1, Jianhua Liu1, Tamra Reed3, Johann Gudjonsson4 and J. Michelle Kahlenberg5, 1University of Michigan, Ann Arbor, MI, 2University of Michigan, Ypsilanti, MI, 3University of Michigan, Ann Arbor, 4University of Michigan, Ann ArborUniversity of Michigan, 5Division of Rheumatology, University of Michigan, Ann Arbor, MI

Meeting: ACR Convergence 2020

Keywords: Inflammation, interferon, skin

  • Tweet
  • Email
  • Print
Session Information

Date: Friday, November 6, 2020

Session Title: Innate Immunity Poster

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Psoriasis is a common, chronic inflammatory autoimmune skin diseases characterized by hyperproliferation and abnormal differentiation of keratinocytes and infiltration of inflammatory cells. Early infiltration of plasmacytoid dendritic cells and detection of an interferon (IFN) signature occurs in many psoriasis lesions.  Recently, we described keratinocyte production of interferon kappa (IFNk) as an important source of type I IFN production in the epidermis.  We thus wanted to explore the role of IFNk in psoriasis.

Methods: We used the well-characterized imiquimod (IMQ) psoriasis model for these studies. 10-week old male and female wild type (WT) and mice transgenic for Ifnk (TG) expressed under the K14 promoter (thus inducing expression only in the epidermis) and mice deficient for Ifnk ( KO) were used.  Psoriasis was induced by topical application of IMQ on both ears for 8 consecutive days (n=6-10 mice per each group. Control mice received Vaseline (n=10 mice per each group).  Animals were monitored daily for ear thickness, lesion severity, and body weight and photo were taken daily.  On day nine, mice were euthanized, and disease severity were compared among all groups via RT-qPCR, immunohistochemistry, and flow cytometry.

Results: For all evaluations, untreated mice did not show any sign of inflammation or disease. While all IMQ treated mice exhibited psoriasis lesions in both ears after 8 days of treatment, development of splenomegaly, ear thickness, cutaneous lesion size and spleen weight were significantly higher in TG mice (p< .001) vs. WT for both male and female mice. The spleen size and ear thickness were significantly smaller in KO mice compared to WT (p< .01). Interestingly, the difference was more exaggerated in TG female vs. male mice.  H&E staining revealed higher number of inflammatory cell infiltrates in IMQ treated TG vs. WT and fewer inflammatory infiltrates in KO mice.  IL-17 and CD8 co-staining of ear tissues revealed greater number of CD8 and IL-17 double-positive cells in IMQ treated TG > WT >KO mice in both male and female groups. Gene expression for type I IFNs, the IFN-regulated gene Mx1, Stat3, and inflammatory cytokines, Il1b, Il17, Tnfa, Il6, Il12 and Il23 were significantly higher in IMQ treated TG >WT >KO (p< 0.05 for all genes tested). While both TG and WT mice demonstrated influx of monocytes by flow cytometry, KO mice did not exhibit a detectible increase after IMQ treatment. No difference in plasmacytoid dendritic cell recruitment was noted between groups.

Conclusion: Overexpression of Ifnk in the epidermis results in increased disease severity after topical application of IMQ, whereas deletion of Ifnk attenuated disease. Although, overexpression of Ifnk alone in the skin does not trigger skin inflammation, our data suggests that epidermal type I IFNs may trigger may act as a rheostat for psoriasis inflammatory responses, driving more inflammatory cells in the skin and promoting a heightened inflammatory and IL-17-oriented response. Together, these data suggest that overproduction of type I IFNs may impact psoriasis development and there may be a role of targeting IFNs in early disease. Further studies will need to elucidate the specific mechanisms that may be at play, especially in human skin.


Disclosure: M. Gharaee-Kermani, None; S. Estadt, None; S. Wolf-Fortune, None; J. Liu, None; T. Reed, None; J. Gudjonsson, Celgene, 2; J. Kahlenberg, AstraZeneca, 5, Bristol Myers Squibb, 2, 5, Eli Lilly, 5, Avion Pharma, 5, Celgene, 2.

To cite this abstract in AMA style:

Gharaee-Kermani M, Estadt S, Wolf-Fortune S, Liu J, Reed T, Gudjonsson J, Kahlenberg J. The Role of Interferon Kappa in Psoriasis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/the-role-of-interferon-kappa-in-psoriasis/. Accessed May 16, 2022.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-role-of-interferon-kappa-in-psoriasis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.